Stephen Aselage is a notable figure in the biotechnology field, having served as CEO of Travere Therapeutics, Inc. from 2014 to 2018. He has a strong educational background with a Bachelor of Science in biology from the University of Notre...
Stephen Aselage is a notable figure in the biotechnology field, having served as CEO of Travere Therapeutics, Inc. from 2014 to 2018. He has a strong educational background with a Bachelor of Science in biology from the University of Notre Dame. Prior to his CEO position, he had extensive experience, including roles at BioMarin and Genzyme, where he focused on commercial development and operations. Under his leadership, Travere achieved performance goals that resulted in significant cash bonuses, showcasing a results-driven approach. He announced his retirement plans in 2018, marking the end of an impactful career in the company and paving the way for a successor. Additionally, Stephen's family ties are evident as his daughter works within the same organization, which reflects a personal commitment to the company and its success. His experience spans over several top roles, and his journey through the biotech industry highlights his knowledge and strategic thinking.